Brexpiprazole CAS 913611-97-9 Purity >99.0% (HPLC) API Factory

Short Description:

Chemical Name: Brexpiprazole

CAS: 913611-97-9

Purity: >99.0% (HPLC)

Appearance: White or Off-White Crystalline Powder

API High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Ruifu Chemical Supply Brexpiprazole Intermediates
Brexpiprazole CAS 913611-97-9
7-Hydroxyquinolinone CAS 70500-72-0
4-Bromobenzo[b]thiophene CAS 5118-13-8
1-(1-Benzothiophen-4-yl)piperazine Hydrochloride CAS 913614-18-3
7-(4-Chlorobutoxy)quinolin-2(1H)-one CAS 913613-82-8
4-Chlorobenzo[b]thiophene CAS 66490-33-3

Chemical Properties:

Chemical Name	Brexpiprazole
Synonyms	OPC-34712; 7-(4-(4-(Benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2(1H)-one
CAS Number	913611-97-9
CAT Number	RF-PI1982
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C25H27N3O2S
Molecular Weight	433.57
Density	1.245±0.060 g/cm3
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	White or Off-White Crystalline Powder
Identification	By IR
RT	Under chirality should complies
Chloride	It gives a reaction of chloride
Water	3.0%~4.5%
Melting Point	198.0~202.0℃
Residue on Ignition	<0.20%
Heavy Metals	≤10ppm
Related Substances
Individual Impurity	<0.50%
Total Impurities	<1.00%
E.E	>99.0%
Purity / Analysis Method	>99.0% (HPLC, on dry basis)
Test Standard	Enterprise Standard
Usage	API

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

FAQ:

Application:

Brexpiprazole (CAS: 913611-97-9) is a drug candidate useful in treatment and prevention of mental disorders including CNS disorders. Brexpiprazole is a novel antipsychotic drug which serves as a serotonin ® dopamine activity modulator and has demonstrated efficacy as an adjunctive treatment in patients with major depressive disorder (MDD). Brexpiprazole exhibits a unique pharmacological profile, acting as a partial agonist of serotonin 5-HT1A and dopamine D2 receptors and as a full antagonist of 5-HT2A and noradrenaline α1B/2C receptors, with similar subnanomolar binding affinity. Brexpiprazole was developed by Otsuka and Lundbeck, was approved in 2015 by the FDA for the treatment of schizophrenia and as an adjunctive treatment for depression. Brexpiprazole is widely considered to be a successor to Otsuka’s antipsychotic drug aripiprazole (trade name Abilify) whose patent expired in August 2014.